T, an in-situ platform combination immunotherapy optimized for solid tumor cancers, has announced the appointment of Stephen ...

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

The global castration-sensitive prostate cancer market is set for sustained double-digit growth, driven by aging populations, ...

Artis BioSolutions, a San Diego, USA-based advanced-therapies development and manufacturing company that launched in April ...

US biotech major Amgen has announced its acquisition of privately-held UK firm Dark Blue Therapeutics, a biotech advancing ...

Positive full results from AstraZeneca’s Phase III TULIP-SC trial have shown the subcutaneous (SC) administration of Saphnelo ...

California-based Cartography Biosciences, an oncology company advancing a pipeline of T-cell engaging bispecific and ...

Switzerland-based Oculis Holding has announced that its neuroprotective candidate privosegtor was granted breakthrough ...

Privately-held Boston, USA-based Nimbus Therapeutics today announced it has entered into a multi-year research collaboration ...

UK analytics group Clarivate (NYSE: CLVT) has published its 2026 Drugs to Watch report, identifying 11 therapies it believes ...

Chinese biotech Shanghai Ark Biopharmaceutical said the country’s medicines regulator has approved Azstarys ...

Earendil Labs, a US AI-driven R&D next-generation biologics therapeutics start-up, has announced an expanded strategic ...